Stephen J. Simko

<i>BRAF-V600E</i> expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups

Marie‐Luise Berres, Karen Phaik Har Lim, Tricia Peters et al. · The Journal of Experimental Medicine · 2014 · 430 citations · Full text

Immunology, Immune Regulation, Pathology +24

Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis

Rikhia Chakraborty, Oliver Hampton, Xiaoyun Shen et al. · Blood · 2014 · 419 citations · Full text

Clofarabine salvage therapy in refractory multifocal histiocytic disorders, including Langerhans cell histiocytosis, juvenile xanthogranuloma and Rosai-Dorfman disease

Stephen J. Simko, Huy D. Tran, Jeremy Jones et al. · Pediatric Blood & Cancer · 2013 · 136 citations

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Jeremy S. Abramson, Matthew Ku, Mark P. Hertzberg et al. · The Lancet · 2024 · 114 citations

Hematological Malignancy, Open-label Trial, Lymphoid Neoplasia +8

Differentiating Skin-Limited and Multisystem Langerhans Cell Histiocytosis

Stephen J. Simko, Benjamin Garmezy, Harshal Abhyankar et al. · The Journal of Pediatrics · 2014 · 101 citations

Cell Pathology, Autoimmune Disease, Cutaneous Biology +7